Holmén A, Murad F, Nilsson K, Rouvelas I, Lindblad M, Szabo E, Halldestam I, Smedh U, Wallner B, Johansson J, Johnsen G, Aahlin EK, Johannessen HO, von Döbeln GA, Hjortland GO, Wang N, Shang Y, Borg D, Quaas A, Bartella I, Bruns C, Schröder W, Nilsson M, Klevebro F, Sunde B (2026)
Health-related quality of life comparing standard and prolonged time-to-surgery after neoadjuvant chemoradiotherapy for esophageal cancer: results from the multicenter, randomized, controlled NeoRes II trial
Dis Esophagus, 39 (3)
DOI 10.1093/dote/doag047, PubMed 42132923

Widder J, Bol GM, Simek IM, Ehret F, Abdel-Aty H, Basic S, Chuter D, Daly J, Fairbrother P, Zeqa D, Aboubakar Nana F, Achard V, Corradini S, Correia D, De Ruysscher D, Dingemans AC, Faivre-Finn C, Gillessen S, Guren MG, Hendriks L, Kunz WG, Lecouvet FE, Levy A, Lievens Y, McDonald F et al. (2026)
Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer: a review and Delphi consensus on behalf of the EORTC-ESTRO OligoCare consortium
Lancet Oncol, 27 (5), e238-e247
DOI 10.1016/S1470-2045(26)00075-6, PubMed 42061381

Butt BP, Sorbye H, Ladekarl M, Stokmo HL, Lothe IMB, Fawad H, Tabaksblat EM, Revheim ME, Dybdahl B, Couvelard A, Perren A, Hjortland GO (2026)
Efficacy of FOLFIRINOX in digestive neuroendocrine carcinoma
J Neuroendocrinol, 38 (4), e70168
DOI 10.1111/jne.70168, PubMed 41911950